EditorialsTherapeutic Hypothermia for Preterm Infants with Hypoxic-Ischemic Encephalopathy: How Do We Move Forward?
References (8)
- et al.
Moderate hypothermia in neonatal encephalopathy: efficacy outcomes
Pediatr Neurol
(2005) - et al.
Safety and short-term outcomes of therapeutic hypothermia in preterm neonates 34-35 weeks gestational age with hypoxic-ischemic encephalopathy
J Pediatr
(2017) - et al.
Cooling for newborns with hypoxic ischaemic encephalopathy
Cochrane Database Syst Rev
(2013) - et al.
The effect of cerebral hypothermia on white and grey matter injury induced by severe hypoxia in preterm fetal sheep
J Physiol
(2007)
Cited by (10)
Correspondence regarding “Outcomes of preterm infants treated with hypothermia for hypoxic-ischemic encephalopathy”
2019, Early Human DevelopmentBehavioral and neuroanatomical outcomes in a rat model of preterm hypoxic-ischemic brain Injury: Effects of caffeine and hypothermia
2018, International Journal of Developmental NeuroscienceCitation Excerpt :Similarly, there are no published rigorous clinical studies of hypothermia as therapy for human infants less than 36 weeks gestation age as far as we are aware, with the exception of a small-scale retrospective study of preterm infants with a GA of 34–35 weeks in which outcomes were compared to term infants. These authors found that cooling at this age was associated with 20% of preterm infants not completing the cooling period, as well as increased hyperglycemia, increased death, and injury primarily in the white matter compared to more gray matter injury in term infants (Laptook, 2017; Rao et al., 2017). Another planned cool-cap study of infants between 32 and 35 weeks GA was halted at an enrollment of 4 infants, possibly due to safety issues and adverse effects (NCT00620711; Walsh, W. (PI), Vanderbilt University).
Acute and long-term NCX activation reduces brain injury and restores behavioral functions in mice subjected to neonatal brain ischemia
2018, NeuropharmacologyCitation Excerpt :These findings could further explain the long-lasting protection of neurounina and, more in general, of other potential NCX activators in this pathology for which therapeutic options are limited. Indeed, the only approved treatment for neonatal hypoxia is hypothermia that can be applied only in specialized medical centers (Laptook, 2017). In addition, hypothermia may be associated with a broad spectrum of side effects that may be more prominent when applied to preterm compared with term infants.
The author serves as Co-PI for ClinicalTrials.gov: NCT01793129. The author declares no conflicts of interest.